Articles

The Yale School of Public Health’s regulatory sciences program expansion builds on the current regulatory affairs track program, which focuses on the administrative, policy, and legal aspects of product regulation.

Tevogen Bio Partners with Yale in Regulatory Sciences Program Expansion 

Common stock of Celularity to commence trading on the Nasdaq Capital Market as “CELU” on July 19, 2021.

Celularity Closes Merger with GX Acquisition Corp 

The US federal government awarded new funding to the National Institute for Innovation in Manufacturing Biopharmaceuticals, including funding under the American Rescue Plan that will be used to advance vaccine manufacturing. 

NIIMBL Receives Federal Funding for Biopharmaceutical Manufacturing Projects

The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.

Continuus Pharmaceuticals Opens Process Development Lab

A new report by Radnor Capital Partners and commissioned by the BIA has shown that international investors are being drawn toward the biotech sector of the UK.

UK Biotech Attracts International Investment, According to New Analysis

Aptamer Group has signed a contract with a global pharmaceutical company to use Optimers to support innovative vaccine development for neurodegenerative disease. 

Aptamer Group Secures Contract with a Global Pharma Company for Vaccine Development

CDMO Idifarma has launched a new service aimed at delivering an accelerated pathway for complex drugs. 

Idifarma Launches New Service for Accelerated Clinical Pathway

EMA's PRAC has found a possible link to very rare cases of myocarditis and pericarditis after vaccination with Comirnaty and Spikevax COVID-19 vaccines.

PRAC Finds Link to Very Rare Cases of Myocarditis and Pericarditis with Comirnaty and Spikevax

After a review of three cases, EMA's PRAC has advised against the use of Janssen’s COVID-19 vaccine in people who have a history of capillary leak syndrome.

EMA Advises Against Using Janssen’s COVID-19 Vaccine in People with Capillary Leak Syndrome

EMA's safety committee, PRAC, has concluded that there is no evidence linking the viral vector in Zynteglo to a blood cancer known as acute myeloid leukemia (AML). 

News